// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

A systematic review of efficacy and safety of chemical thromboprophylaxis in renal transplantation

R. Kohli - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Heparin

The optimal anticoagulation during catheter ablation of atrial fibrillation: a systematic review and network meta‐analysis

Y. Zhao - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Pradax

UK NEQAS for blood coagulation D‐dimer Point of care testing programme

D. Kitchen - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Observational study of outcomes in patients with antiphospholipid syndrome anticoagulated with Rivaroxaban

T. W. Htut - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Antiphospholipid syndrome

rivaroxaban

External quality assurance (EQA) for the thromboelastometry devices: UK NEQAS BC programme update

D. Kitchen - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

rivaroxaban

Thromboembolism in adult patients with acute lymphoblastic leukaemia / lymphoma: past and future practice in a tertiary centre

A. Bond - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Asparaginase

The differential surface expression of tissue factor between monocyte subsets

K. Musgrave - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sepsis

N/A

A case series of anticoagulation in mechanical and valvular heart disease in pregnancy

K. White - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac valvular dysplasia X-linked

Enoxaparin

Anticoagulation in palliative and end of life care ‐ results of a supra‐regional audit and literature review

K. Moss - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

The CAVEaT multicentre audit of venous thrombosis in patients with haematolical malignancy and thrombocytopenia: preliminary results.

S. Booth - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute promyelocytic leukemia

Heparin

Dynamic and time‐to‐event analyses demonstrate marked reduction in transfusion requirements for janus kinase inhibitor–naïve myelofibrosis patients treated with momelotinib compared head to head with ruxolitinib

D. McLornan - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Systemic inflammation

Momelotinib

A national survey and simulation study of pre‐hospital whole blood transfusion: what are the benefits?

H. Tucker - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Trauma

N/A

A feasibility study on the provision of extended matched red cells for transfusion support in chronic haematological diseases

S. Henton - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelodysplastic Syndrome

N/A

Rh antibodies in patients with sickle cell disease – an on‐going challenge

C. S. Booth - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Group O D negative blood – promoting the appropriate use of an essential but limited resource

S. Allard - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Does early discharge affect administration of anti‐D Ig prophylaxis

C. Spinks - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Red cell alloimmunisation in patients receiving Veno‐Venous Extracorporeal membrane oxygenation (VV‐ECMO)

D. Jayakody Arachchillage - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Reduction of platelet thresholds to adhere with British Society of Haematology (BSH) guidance for tunnelled central line insertion does not increase bleeding complication in haematology patients; a single centre experience

L. Carter-Brzezinski - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Alloimmunisation in sickle cell disease in the North Central London sickle cell cohort: providing a baseline for extended red cell antigen matching and targeted donor genotyping

K. Fordwor - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Incorrect plasma components transfused: when it comes to ABO compatibility Do we need to stop only ever ‘seeing red’?

V. Tuckley - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved